Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide orodispersible tablets for prevention of esophageal stricture after endoscopic submucosal dissection
2018-002617-35Phase 2Recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of budesonide in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Primary efficacy endpoint. Started May 2019; status: recruiting.
02
Drugs
budesonide
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2018-002617-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002617-35.